Details for New Drug Application (NDA): 214226
✉ Email this page to a colleague
NDA 214226 describes TENOFOVIR ALAFENAMIDE, which is a drug marketed by Lupin Ltd and Apotex and is included in two NDAs. Additional details are available on the TENOFOVIR ALAFENAMIDE profile page.
The generic ingredient in TENOFOVIR ALAFENAMIDE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
The generic ingredient in TENOFOVIR ALAFENAMIDE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
Summary for 214226
| Tradename: | TENOFOVIR ALAFENAMIDE |
| Applicant: | Lupin Ltd |
| Ingredient: | tenofovir alafenamide fumarate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE | ||||
| Approval Date: | Mar 30, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
